Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24240276 | 0.74 | CYP1A2 (0.46) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL23071933 | 0.70 | CYP1A2 (0.42) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL732152 | 0.69 | — | — | |
| SCHEMBL3552310 | 0.69 | IRAK4 (0.31) | — | |
| SCHEMBL24240164 | 0.69 | BPTF (0.39) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL21623939 | 0.69 | CYP1A2 (0.38) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL30232693 | 0.69 | KCNJ1 (0.36) | ALDH1A1 | |
| SCHEMBL30643765 | 0.69 | BPTF (0.39) | CYP1A2BPTFCHRNB2CHRNA4KMT2A | |
| SCHEMBL26107606 | 0.69 | KCNJ1 (0.36) | ALDH1A1 | |
| SCHEMBL7674620 | 0.68 | GRM5 (0.56) | CYP1A2KMT2ARAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-09-14 | — | — | US | disclosed |
| EP-3992188-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3950683-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | Boehringer Ingelheim International GmbH (DE) | 2022-02-09 | — | — | EP | disclosed |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-05-20 | — | — | US | disclosed |
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941137-B2 | Difluoromethyl-phenyl triazoles | GABRA5, GABRB1, GABRA1 | CYP1A2 164/4885BPTF 2265/4885CHRNB2 157/4885 |
| US-20230286946-A1 | DIFLUOROMETHYL-PYRIDIN-2-YL TRIAZOLES | GABRA5, GABRA3, GABRA2 | CYP1A2 150/4885BPTF 2285/4885CHRNB2 61/4885 |
| US-20210147393-A1 | DIFLUOROMETHYL-PHENYL TRIAZOLES | GABRA5, GABRB1, GABRA1 | CYP1A2 157/4885BPTF 2248/4885CHRNB2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.